Anya Biopharm Current Assets

What does Anya Biopharm do? Anya Biopharm Inc generates revenue by researching and developing oral peptide dosage form platforms and new drug products within the pharmaceuticals industry. The company leverages its MIRA/JE oral peptide formulation platform to create lead products, most notably ANY002, which is a glucagon-like peptide-1 (GLP-1) receptor agonist designed for the treatment of type 2 diabetes and obesity. This core asset has advanced through early clinical pharmacokinetic trials in both animals and humans, establishing the company's value proposition in the biotech sector. The firm also markets its proprietary oral dosage form technology through the development of ANY004, which is currently in preclinical development. By focusing on these specific drug projects and formulation platforms, Anya Biopharm Inc targets the professional biotech and pharmaceutical business segments. The company operates from its headquarters in Taipei City, Taipei, and serves the global market for innovative diabetes and obesity treatments through its specialized research and development capabilities. Anya Biopharm is one of the most popular companies on Eulerpool.